Breast Cancer
FDA Approves Neratinib Combination for HER2+ Breast Cancer
BY GINA COLUMBUS
FDA Accepts BLA for Pertuzumab/Trastuzumab Combo for HER2+ Breast Cancer
BY JASON M. BRODERICK
Life on the Other Side of the Hospital Gown
BY PATRICIA JAKEL, MN, RN, AOCN
Genetics: Discovering the Unknown in Breast Cancer
BY BRIELLE BENYON
Immunotherapy Plus Chemo Improves Metastatic TNBC Outcomes
BY GINA COLUMBUS
More Immunotherapy May Enter TNBC Space
BY JESSICA HERGERT
Unmet Needs Remain in TNBC Treatment
BY KRISTI ROSA
Ovarian Suppression Plus AI Treatment Can Have Major Adverse Events
BY DAWN L. HERSHMAN, MD, MS
Radiation's Role Shifts in Breast Cancer
BY JESSICA HERGERT
External Resources
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.